PT2554172E - Método para o tratamento de doenças - Google Patents

Método para o tratamento de doenças Download PDF

Info

Publication number
PT2554172E
PT2554172E PT120073622T PT12007362T PT2554172E PT 2554172 E PT2554172 E PT 2554172E PT 120073622 T PT120073622 T PT 120073622T PT 12007362 T PT12007362 T PT 12007362T PT 2554172 E PT2554172 E PT 2554172E
Authority
PT
Portugal
Prior art keywords
diseases
treatment
Prior art date
Application number
PT120073622T
Other languages
English (en)
Inventor
David Bar-Or
Original Assignee
Ampio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ampio Pharmaceuticals Inc filed Critical Ampio Pharmaceuticals Inc
Publication of PT2554172E publication Critical patent/PT2554172E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
PT120073622T 2009-06-22 2010-06-22 Método para o tratamento de doenças PT2554172E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21918509P 2009-06-22 2009-06-22
US31535010P 2010-03-18 2010-03-18

Publications (1)

Publication Number Publication Date
PT2554172E true PT2554172E (pt) 2014-11-07

Family

ID=43354875

Family Applications (5)

Application Number Title Priority Date Filing Date
PT107925679T PT2326332E (pt) 2009-06-22 2010-06-22 Método para o tratamento de doenças
PT120073622T PT2554172E (pt) 2009-06-22 2010-06-22 Método para o tratamento de doenças
PT120073614T PT2554171E (pt) 2009-06-22 2010-06-22 Método para o tratamento de doenças
PT110092392T PT2425839E (pt) 2009-06-22 2010-06-22 Método para o tratamento de doenças
PT120073655T PT2554174E (pt) 2009-06-22 2010-06-22 Método para o tratamento de doenças

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT107925679T PT2326332E (pt) 2009-06-22 2010-06-22 Método para o tratamento de doenças

Family Applications After (3)

Application Number Title Priority Date Filing Date
PT120073614T PT2554171E (pt) 2009-06-22 2010-06-22 Método para o tratamento de doenças
PT110092392T PT2425839E (pt) 2009-06-22 2010-06-22 Método para o tratamento de doenças
PT120073655T PT2554174E (pt) 2009-06-22 2010-06-22 Método para o tratamento de doenças

Country Status (25)

Country Link
US (4) US9233113B2 (pt)
EP (7) EP2554174B1 (pt)
JP (2) JP5833549B2 (pt)
KR (1) KR101877041B1 (pt)
CN (3) CN107050036A (pt)
AU (1) AU2010264524B2 (pt)
BR (1) BRPI1010087A2 (pt)
CA (2) CA2751002C (pt)
DE (1) DE202010017530U1 (pt)
DK (6) DK2554173T3 (pt)
EA (1) EA027524B1 (pt)
ES (6) ES2612748T3 (pt)
HK (3) HK1153127A1 (pt)
HR (1) HRP20130123T1 (pt)
HU (1) HUE028212T2 (pt)
IL (1) IL216951A (pt)
MX (2) MX2011013777A (pt)
MY (1) MY160127A (pt)
NZ (2) NZ615941A (pt)
PL (6) PL2554172T3 (pt)
PT (5) PT2326332E (pt)
SG (7) SG2014008163A (pt)
SI (1) SI2326332T1 (pt)
WO (1) WO2010151530A1 (pt)
ZA (1) ZA201109278B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
DE202006021081U1 (de) * 2005-07-12 2012-05-08 Dmi Biosciences, Inc. Produkte zur Behandlung von Krankheiten
CA2765883A1 (en) * 2009-06-22 2010-12-29 Dmi Acquisition Corp. Methods and products for treatment of diseases
CA2751002C (en) 2009-06-22 2012-09-11 Dmi Acquisition Corp. Method for treatment of diseases
EP2763678A1 (en) * 2011-10-07 2014-08-13 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
EP2904102B1 (en) * 2012-10-02 2018-11-21 Centenary Institute of Cancer Medicine & Cell Biology Modulation of rna activity and vascular permeability
BR112015014261A8 (pt) * 2012-12-19 2019-10-08 Ampio Pharmaceuticals Inc composto de danazol, seu uso e formulação farmacêutica compreendendo este
JP6057333B2 (ja) * 2013-02-25 2017-01-11 国立大学法人浜松医科大学 血管透過性亢進抑制作用の評価方法
US9880778B2 (en) 2015-11-09 2018-01-30 Google Inc. Memory devices and methods
WO2019090171A1 (en) * 2017-11-04 2019-05-09 Massachusetts Institute Of Technology Compositions and methods to increase muscular strength

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3135743A (en) 1960-06-29 1964-06-02 Sterling Drug Inc Steroido[2. 3-d]isoxazoles and preparation thereof
NL104564C (pt) 1958-07-23
GB1123770A (en) 1966-11-15 1968-08-14 Sterling Drug Inc 2-cyano-3-oxo-steroids
US4160027A (en) * 1977-12-20 1979-07-03 Sterling Drug Inc. Steroid cyanoketones and intermediates
FR2502098A1 (fr) 1981-03-23 1982-09-24 Huret & Fils Dispositif perfectionne de fixation d'un derailleur sur une patte de cadre
US4994443A (en) * 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5714481A (en) * 1983-08-02 1998-02-03 Research Corporation Technologies, Inc. Derivatives of 5-androsten-17 ones and 5-androstan-17-ones
US4617299A (en) 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4837212A (en) * 1984-11-15 1989-06-06 University Of Miami Treatment of hemolytic anemia with danazol
US4975537A (en) * 1985-10-23 1990-12-04 The Upjohn Company Δ9(11) -angiostatic steroids
AU604236B2 (en) 1986-04-28 1990-12-13 Iolab, Inc. Intraocular dosage compositions and method of use
DE3738620A1 (de) 1987-11-13 1989-05-24 Luderschmidt Christoph Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
US5407926A (en) 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
JP2680614B2 (ja) 1988-08-01 1997-11-19 日清製粉株式会社 ダナゾール組成物
US5990099A (en) * 1988-10-31 1999-11-23 Alcon Laboratories, Inc. Angiostatic agents and methods and compositions for controlling ocular hypertension
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
KR0181264B1 (ko) * 1989-07-07 1999-03-20 라브리 페르낭 성스테로이드 활성 억제용 안드로겐 유도체
DE69132048T2 (de) 1990-06-11 2000-07-13 Alcon Laboratories Inc.(N.D.Ges.D.Staates Delaware), Forth Worth Verwendung von Steroiden zur Inhibierung von Angiogenesis
US5972922A (en) * 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
JPH04149132A (ja) 1990-10-13 1992-05-22 Bairon Boeki Kk ダナゾール水溶液
JPH0735335B2 (ja) 1991-02-28 1995-04-19 五十嵐 正雄 子宮内膜症の治療薬
ATE185071T1 (de) * 1991-06-18 1999-10-15 Theramex Steroide enthaltende zusammensetzungen zur anwendung am auge und ihre verwendung zur behandlung des glaukoms
CA2123405C (en) 1991-11-22 2008-01-15 Abbot F. Clark Angiostatic steroids
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
GB9200210D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
DK0643581T3 (da) * 1992-04-21 2000-04-25 Schepens Eye Res Inst Okulær androgenbehandling ved Sjögren's syndrom
ES2068742B1 (es) 1993-02-11 1995-11-16 Uriach & Cia Sa J Nuevos derivados de piridinio.
WO1995003807A1 (en) * 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
CA2185699A1 (en) 1994-04-04 1995-10-12 William R. Freeman Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
US5885591A (en) 1996-07-02 1999-03-23 Johnson & Johnson Consumer Products, Inc. Personal lubricant compositions
US5929111A (en) * 1996-12-18 1999-07-27 Alcon Laboratories, Inc. A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
WO1998043647A1 (en) * 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation of amyloid precursor protein (app) expression by estrogenic compounds
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
EP0939124A3 (en) 1998-02-24 2001-03-21 Smithkline Beecham Plc MGBP1 sequences
US6645954B2 (en) * 1998-04-09 2003-11-11 Multimed Limited Compositions comprising ethisterone or its derivatives
GB9807809D0 (en) 1998-04-09 1998-06-10 Multimed Ltd Compositions comprising ethisterone or its derivatives
CN1311684A (zh) 1998-07-10 2001-09-05 悉尼大学 黄斑变性中新生血管形成的预防治疗
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
ATE225405T1 (de) 1999-07-09 2002-10-15 Pasteur Institut Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit
US6610674B1 (en) * 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
PT1221917E (pt) * 1999-10-21 2005-04-29 Alcon Inc Dispositivo para ministrar medicamentos
WO2001030337A2 (en) 1999-10-22 2001-05-03 Orbon Corporation Ophthalmic formulation of dopamine antagonists
US6562369B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
AU2001230864A1 (en) 2000-01-12 2001-07-24 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
GB2345851B (en) 2000-01-18 2004-05-26 Gavin Paul Vinson A combination of trilostane or keto-trilostane and an anti-oestrogen for the treatment of an oestrogen-dependent cancer or tumour
US20020055512A1 (en) * 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
EP1938799B1 (en) 2000-03-10 2013-05-08 Insite Vision Incorporated Compositions for treating and preventing posterior segment ophthalmic disorders and use thereof
ES2381775T3 (es) 2000-08-04 2012-05-31 Dmi Biosciences, Inc. Procedimiento del uso de dicetopiperazinas y composición que las contiene
US20040082557A1 (en) * 2001-01-26 2004-04-29 Wajszczuk Charles Paul Methods for treating estrogen-dependent disorders
AU2002244247B2 (en) 2001-03-01 2007-12-13 Harbor Biosciences, Inc. Use of certain steroids for treatment of blood cell deficiencies
GB2375958B (en) * 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20030003144A1 (en) * 2001-05-01 2003-01-02 Keller Brian C. Sustained release formulations for nifedipine, dextromethorphan, and danazol
JP2005500025A (ja) 2001-05-29 2005-01-06 サーナ・セラピューティクス・インコーポレイテッド 女性生殖疾病及び状態の核酸に基づく調節
FR2825277B1 (fr) * 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
US20030050291A1 (en) * 2001-06-12 2003-03-13 Yadon Arad Adrenal enzyme inhibitors
US20030232798A1 (en) * 2001-06-12 2003-12-18 Yadon Arad Adrenal enzyme inhibitors
WO2003013609A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
EP2298315A1 (en) * 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
ATE324880T1 (de) 2002-12-18 2006-06-15 Besins Int Lab Behandlung von mastalgie mit4-hydroxy-tamoxifen
CA2511217A1 (en) * 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US7812010B2 (en) 2003-01-02 2010-10-12 Femmepharma, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
CN100342856C (zh) * 2003-04-10 2007-10-17 上海医药工业研究院 达那唑半固体骨架制剂的组合物
GB2400554B (en) 2003-04-16 2007-04-18 George Margetts Treatment of angiotensin II-induced cardiovascular disease
WO2004103406A1 (ja) 2003-05-26 2004-12-02 Japan Science And Technology Agency 血小板の減少または増加を伴う疾患の治療用組成物
GB0313612D0 (en) * 2003-06-12 2003-07-16 Novartis Ag Organic compounds
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005053660A2 (en) * 2003-12-03 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising danazol
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20050143362A1 (en) * 2003-12-31 2005-06-30 Mclane Michael W. Danazol for treatment of hypogonadism in the adult male
US7442681B2 (en) * 2004-02-10 2008-10-28 University Of Virginia Patent Foundation Method of inhibiting vascular permeability
US20050266005A1 (en) 2004-02-27 2005-12-01 Heavner George A Methods and compositions for treating IL-3 related pathologies
EP1737452A1 (en) 2004-04-06 2007-01-03 Angiogenetics Sweden AB Angiogenesis-affecting compounds and methods of use thereof
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
CA2572223C (en) * 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
GB2420281A (en) 2004-11-22 2006-05-24 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of dermatological conditions
GB2421183A (en) 2004-12-17 2006-06-21 Stegram Pharmaceuticals Ltd Topical formulations for use in the treatment or prevention of skin cancers
EP1848541A4 (en) 2005-02-07 2013-01-16 Pharmalight Inc METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS
US8841259B2 (en) 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
US20060211662A1 (en) 2005-03-02 2006-09-21 Du Mee Charles P Combination therapy for topical application in the treatment of age-related macular degeneration and ocular hypertension
DE202006021081U1 (de) 2005-07-12 2012-05-08 Dmi Biosciences, Inc. Produkte zur Behandlung von Krankheiten
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20100330148A1 (en) * 2006-03-20 2010-12-30 The Johns Hopkins University Mehods and compositions for inhibiting impdh-1 isoform 1
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US8071779B2 (en) * 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
CN101024082A (zh) 2007-04-06 2007-08-29 张士东 一种全面预防和治疗心脑血管疾病复方药及其应用
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
WO2009036108A1 (en) * 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
WO2009073843A1 (en) 2007-12-06 2009-06-11 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
WO2009146320A1 (en) * 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
CA2765883A1 (en) * 2009-06-22 2010-12-29 Dmi Acquisition Corp. Methods and products for treatment of diseases
CA2751002C (en) 2009-06-22 2012-09-11 Dmi Acquisition Corp. Method for treatment of diseases
EP2763678A1 (en) 2011-10-07 2014-08-13 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
BR112015014261A8 (pt) 2012-12-19 2019-10-08 Ampio Pharmaceuticals Inc composto de danazol, seu uso e formulação farmacêutica compreendendo este

Also Published As

Publication number Publication date
JP2012530784A (ja) 2012-12-06
ES2523821T3 (es) 2014-12-01
SG176939A1 (en) 2012-01-30
EP2425839A1 (en) 2012-03-07
EA201200036A1 (ru) 2012-08-30
EP2554174A1 (en) 2013-02-06
US20120077789A1 (en) 2012-03-29
US9987292B2 (en) 2018-06-05
EP2554170A1 (en) 2013-02-06
HK1176870A1 (zh) 2013-08-09
PT2326332E (pt) 2013-01-28
CA2781771A1 (en) 2010-12-29
SG2014008171A (en) 2014-04-28
SG2014009781A (en) 2014-04-28
MX336436B (es) 2016-01-19
EA027524B1 (ru) 2017-08-31
IL216951A (en) 2017-08-31
EP2326332A4 (en) 2011-11-16
PL2326332T3 (pl) 2013-05-31
AU2010264524B2 (en) 2015-03-19
DE202010017530U1 (de) 2012-03-28
EP2554171A1 (en) 2013-02-06
DK2425839T3 (en) 2014-11-17
KR20120102574A (ko) 2012-09-18
NZ615941A (en) 2015-05-29
ES2554688T3 (es) 2015-12-22
EP2554174B1 (en) 2015-09-02
HUE028212T2 (en) 2016-12-28
EP2554172B1 (en) 2014-08-13
SG2014008155A (en) 2014-04-28
US9233113B2 (en) 2016-01-12
ES2523769T3 (es) 2014-12-01
PL2554171T3 (pl) 2015-03-31
CN106109475A (zh) 2016-11-16
PL2554174T3 (pl) 2016-03-31
EP2326332B1 (en) 2012-11-14
US20120035147A1 (en) 2012-02-09
WO2010151530A1 (en) 2010-12-29
AU2010264524A1 (en) 2012-01-19
SG2014009799A (en) 2014-04-28
EP2326332A1 (en) 2011-06-01
EP2425839B1 (en) 2014-08-13
EP2554171B1 (en) 2014-08-13
PL2554172T3 (pl) 2015-03-31
EP2554172A1 (en) 2013-02-06
MX2011013777A (es) 2012-04-20
DK2554173T3 (en) 2017-01-16
CA2751002A1 (en) 2010-12-29
EP2554173A1 (en) 2013-02-06
MY160127A (en) 2017-02-28
KR101877041B1 (ko) 2018-07-10
CN107050036A (zh) 2017-08-18
ES2523068T3 (es) 2014-11-20
US8227457B2 (en) 2012-07-24
HK1176003A1 (en) 2013-07-19
PT2554174E (pt) 2015-12-15
ES2612748T3 (es) 2017-05-18
CA2751002C (en) 2012-09-11
PL2425839T3 (pl) 2015-03-31
US20160175326A1 (en) 2016-06-23
US20100324005A1 (en) 2010-12-23
PT2554171E (pt) 2014-11-06
SG2014008163A (en) 2014-04-28
BRPI1010087A2 (pt) 2019-07-16
JP5833549B2 (ja) 2015-12-16
IL216951A0 (en) 2012-02-29
DK2554174T3 (da) 2015-12-07
ES2398322T3 (es) 2013-03-15
DK2326332T3 (da) 2013-03-04
PL2554173T3 (pl) 2017-06-30
SI2326332T1 (sl) 2013-03-29
PT2425839E (pt) 2014-11-17
DK2554172T3 (da) 2014-11-17
SG2014009807A (en) 2014-04-28
CN102481304A (zh) 2012-05-30
DK2554171T3 (da) 2014-11-17
EP2554173B1 (en) 2016-10-05
HRP20130123T1 (hr) 2013-03-31
HK1153127A1 (en) 2012-03-23
JP2015214575A (ja) 2015-12-03
NZ597030A (en) 2013-10-25
ZA201109278B (en) 2013-05-29

Similar Documents

Publication Publication Date Title
HK1217763A1 (zh) 用於治療疾病的方法
HK1169804A1 (zh) 治療疼痛的方法
HK1176870A1 (zh) 疾病的治療方法
PT2429524T (pt) Formulação de ac220 seca por atomização
EP2350641A4 (en) Methods of Treatment
EP2544686A4 (en) COMBINED METHODS FOR THE TREATMENT OF DISEASES
EP2416803A4 (en) NEW METHODS OF TREATING INFLAMMATORY DISEASES
PL2281457T3 (pl) Sposób fizycznego działania na rośliny
EP2424539A4 (en) PROCESS FOR TREATING DEPRESSION
EP2585103A4 (en) METHOD OF TREATMENT
EP2440238A4 (en) Methods of Treatment
GB0909807D0 (en) Method of treatment
GB0904164D0 (en) Method of treatment
GB0921823D0 (en) Method of treatment
AU2009903360A0 (en) Method of Treatment
EP2532254A4 (en) METHOD FOR PROCESSING A LACTO-N BIOSE-CONTAINED SOLUTION
GB0823435D0 (en) Method of treatment
GB201000318D0 (en) Method of treatment